News & Events | InSitu Biologics - Opiod-Free Pain Management

InSitu Biologics Announces Co-Development Agreement With Mayo Clinic

Dec 22, 2022

InSitu Biologics is pleased to announce that it has entered into an agreement with the Mayo Clinic to further develop its...

Nov 17, 2022

InSitu Biologics will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain...

Apr 22, 2022

InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board. For more...

Mar 30, 2022

InSitu Biologics will share the latest investigational work on its hydrogel-lipid-microparticle matrix at the upcoming 47th Annual...

Mar 14, 2022

InSitu Biologics was formally welcomed into in5, one of the UAE's leading incubators, last month by in5's Board of Directors. In5...

Dec 28, 2021

InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in...

Oct 29, 2021

The American Society of Regional Anesthesia has chosen InSitu Biologics’ INSB200™ poster as a Best of Meeting presentation in Emerging...

Aug 9, 2021

InSitu Biologics has had a very productive summer. We received positive pre-clinical animal study results on our lead product, had...

Apr 15, 2021

InSitu Biologics is off to a fast start in 2021. We completed a successful financing round, made great strides in our R&D efforts,...

Dec 18, 2020

Insitu Biologics had several key accomplishments in 2020, setting the stage for an even better 2021. We significantly reduced our...